Melinda Pruis
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing.
Back to newsMore news
Accreditation renewed
In October 2020, we received formal notification of the renewal of our accreditation of ISO17025: 2005 into the 2017 version. We …
Hartwig tools now available as a nextflow nf-core pipeline called oncoanalyser
The University of Melbourne Centre for Cancer Research (UMCCR) Genomics Platform Group, led by Professor Oliver Hofmann, has collaborated with …
In search of the optimal treatment strategy for glioblastoma
Patients with recurrent glioblastoma have an unfavorable outlook and few treatment options. The recently launched GLOW study should change this …
Cancer is caused by DNA mutations. There are an increasing number of drugs available that act on specific errors in the DNA of an individual patient’s tumor. A drug that doesn’t fit, like a key in a lock, will not work, while the risk of side effects remains.